FibroGen
Van Pell Gerard has extensive experience in IT operations and consulting, currently serving as IT Operations Manager at FibroGen since July 2008, where responsibilities include overseeing IT operations. Previously, Van Pell Gerard held the position of Senior LAN Administrator at FibroGen and worked as an IT Consultant at Proteolix, Inc. from 2006 to 2008 and at Tularik from 1992 to 1996. Educational background includes a degree from Rutgers University, completed between 1980 and 1985.
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.